UTEST grad TrendMD makes Canadian national media splash

TrendMD_logo copyTrendMD, a medical publishing company that helps doctors, researchers, and professionals in STEM-related fields to find the most relevant content amid an unending sea of daily publications, was recently featured in a Canadian Press article by Adam Miller.

The article was published on CBC.ca, CTV.caWaterloo Record, Sing Tao Daily, World Journal, Surrey Leader, Metro News, Winnipeg Free Press, Brampton Guardian, Ottawa Citizen, 660 News Radio, Canadian Business, Times Colonist, Yahoo News, Soo Today, Lethbridge Herald and YorkRegion.com, among other sources.

Paul Kudlow, CEO and co-founder of TrendMD.

Paul Kudlow, CEO and co-founder of TrendMD.

The company is part of the second UTEST cohort and was founded by Paul Kudlow, a Toronto-based physician-scientist.

The program is co-directed by MaRS Innovation and the University of Toronto.

Here’s an excerpt:

“Everything starts with the information overload problem. Today, there are now over 4,000 new articles that are published per day, and that’s just in biomedicine alone,” says Paul Kudlow, a Toronto-based physician-scientist and founder of TrendMD, a startup financially backed by MaRS Innovation and the Ontario Centres of Excellence.

Kudlow says the amount of published medical research is growing and is spread throughout an estimated 27,000 medical journals, making it nearly impossible to keep up with the latest developments. (more…)

Encycle Therapeutics developing lead molecule to tackle inflammatory bowel disease

Company’s collaborative partnership with IRICoR, Université de Montréal and MaRS Innovation, funded by Merck Canada, to advance macrocycle drug

Encycle IRICoR release

Encycle Therapeutics Inc., a biotechnology start-up founded by the University of Toronto in partnership with MaRS Innovation, is developing its lead orally-bioavailable macrocycle drug to target integrin a4b7, which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease.

TORONTO and MONTREAL, Nov. 10, 2014 — Encycle Therapeutics Inc., a biotechnology start-up founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, is developing its lead orally-bioavailable macrocycle drug to target integrin a4b7, which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease.

This announcement was covered in Drug Discovery & Development, PBR, Yonge Street Media, Biotechnology Focus, and Bioworld Today (no public link available).

Read this release in French.

To support and advance this molecule, Encycle Therapeutics is collaboratively partnering with the Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR), the Université de Montréal (UdeM) and MaRS Innovation. The partnership builds on the Merck Canada Inc. $4 million public-private funding partnership, announced at BIO in April 2013, to develop collaborative research projects with three Canadian academic commercialization centres, including MaRS Innovation and IRICoR.

“We are pleased to help support this important research collaboration that is made possible through the Quebec-Ontario corridor project in an emerging technology area. IRICoR, MaRS Innovation and Encycle have clearly leveraged their respective strengths to accelerate the discovery of novel therapeutics. As a research-focused company committed to early stage private-public partnering, we believe that such interactions will continue to fuel innovation in the life science sector in Canada,” said Mr. Chirfi Guindo, president and managing director, Merck Canada Inc.

The agreement brings a significant investment to fund Encycle Therapeutics’ development work, giving IRICoR an equity position and expanding MaRS Innovation’s equity stake. Cumulatively, Encycle Therapeutics has secured more than $2.5 million to advance its drug development platform. (more…)

AvidBiologics and National Research Council of Canada to collaborate on antibody-drug conjugates

AvidBiologics Inc.Toronto-based AvidBiologics Inc., a leading Canadian biotech company, and the National Research Council of Canada (NRC) are collaborating on one of the most promising advances in the fight against cancer: antibody-drug conjugates (ADCs).

Recently signed research and licensing agreements will enable both organizations to continue developing a series of ADCs targeting breast, lung, and head-and-neck cancers. Unlike chemotherapy, ADCs specifically seek and destroy cancer cells, with minimal impact on healthy cells.

“The work performed by NRC is crucial to assembling the data package needed for clinical trials,” said Ilia A. Tikhomirov, president and CEO of Avid Biologics, which focuses exclusively on ADCs. “We are privileged to be able to continue the rapid development of our lead candidate while advancing the other candidates in the pipeline in collaboration with the NRC. We thank the NRC and all of our partners for their support as AvidBiologics transitions from a discovery-stage to a development-stage company.” (more…)

Triphase announces Celgene collaborations and license deal with PharmAbcine

Triphase-logo-WebTriphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, announced October 27, 2014 new and expanded strategic collaborations with Celgene Corporation.

This announcement was covered in Genetic Engineering and Biotechnology News (GEN), BioCentury Extra (no link available), Pharmaceutical Business Review (no link available), Scrip and BioWorld Today (no link available). It builds on Triphase’s original collaborative agreement with Celgene in January 2014.

The company has also announced a new global license for a fully human, bi-specific antibody targeting VEGFR-2/TIE 2 with Korea’s PharmAbcine.

Triphase initiates Phase I Study Evaluating Marizomib in Glioblastoma (GBM) with Celgene

Triphase has expanded its strategic collaboration with Celgene Corporation. The supplemental agreement adds a Phase I development program that will explore combining an intravenous (IV) formulation of marizomib with bevacizumab in glioblastoma (GBM), an aggressive malignant primary brain tumour. (more…)

BioCentury features Vasomune Therapeutics

Vasomune Therapeutics logoVasomune Therapeutics, a MaRS Innovation start-up company from Sunnybrook Health Sciences Centre’s Sunnybrook Research Institute, was featured in a BioCentury emerging company profile by Michael J. Haas.

The company is currently raising a Series A financing round and recently closed a seed investment with Genome Canada and an unnamed industry partner. MaRS Innovation also contributed a third of the investment, bringing the round’s total to $1.5 million.

Haas’ profile, “Vasomune: Lassoing Tie2,” is available behind a paywall on the BioCentury website.

Here’s a short excerpt:

Agonizing Tie2 could restore vascular integrity and limit tissue damage in kidney injury, but bringing together the four copies needed to activate the receptor is a job too big for small molecules or antibodies. Vasomune Therapeutics Inc. has shown its four-armed peptidomimetic, vasculotide, activates Tie2 and restores vascular integrity in [preclinical]  models.

“Many renal diseases are ultimately characterized by a loss in vascular integrity that damages tubules in the kidney,” CEO Parimal Nathwani said. “Our idea is to use vasculotide to fix the problem and restore normal vascular integrity before it gets out of control.” (more…)

Vasomune Therapeutics awarded $1.5 million to advance lead asset for renal disease

Vasomune Therapeutics logoTORONTO (October 20, 2014) — Vasomune Therapeutics, a biotechnology start-up founded by Drs. Dan Dumont and Paul Van Slyke of Sunnybrook Research Institute (SRI) in partnership with MaRS Innovation, has received $1.5 million, in part through Genome Canada’s Genomic Applications Partnership Program (GAPP), to advance Vasculotide, the company’s lead Tie-2 activating agent, towards clinical development.

This announcement was covered in Biotechnology Focus.

The Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, announced the funding as part of 12 selected projects under Genome Canada’s Genomic Applications Partnership Program (GAPP), on October 15 in Wallenstein, Ontario.

Parimal Nathwani

Parimal Nathwani, president and CEO of Vasomune Therapeutics Inc.

“We believe that our technology is well positioned to accelerate from preclinical research into clinical development based on its strong data package,” said Parimal Nathwani, president and CEO of Vasomune Therapeutics. “This award, in combination with industry funding, validates the Vasculotide opportunity and gives us the required funds to advance the drug candidate toward the clinic.”

In preclinical studies, Vasculotide has shown to be an effective treatment for multiple renal diseases including acute kidney injury (AKI), which in humans is a possible outcome of kidney function loss that manifests in nearly a third of high-risk cardiac patients. AKI may result from short-term interruptions in blood flow during surgery; 11 percent of patients who develop AKI after bypass surgery will die. People who survive AKI are at risk of developing longer-term kidney complications such as chronic kidney disease or End Stage Renal Disease. Vasomune’s founders conceptualized and designed Vasculotide to bind to the Tie-2 receptor, which is responsible for maintaining vascular health (and thus blood flow).

With this new funding, a third from Vasomune and MaRS Innovation, a third from Genome Canada and a third from a leading multinational pharmaceutical company, Vasomune can transition its program into manufacturing optimization, pharmacokinetics and toxicology studies to prepare for clinical development in early 2016. (more…)

Xagenic announces $6 million GAAP partnership for Hepatitis C testing; appoints president and CEO

Xagenic 2014 logoXagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, announced October 15, 2014 that its project in partnership with the University of Toronto was successful in securing funding from Genome Canada under the Genomic Applications Partnership Program (GAPP).

The funding, announced by the Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, is part of 12 selected projects under Genome Canada’s Genomic Applications Partnership Program (GAPP), on October 15 in Wallenstein, Ontario.

The project titled “Development of Low Cost Testing Chip and Device for Hepatitis C Testing” was approved with funding up to a maximum of $5,999,865 over three years. The Ontario Ministry of Research and Innovation is supporting the project with a grant matching the Genome Canada contribution.

“This is a tremendous opportunity for us to leverage the viral assay development and electrochemical detection expertise in the labs of Dr. Shana Kelley and Dr. Edward Sargent at the University of Toronto to significantly advance our own research programs on several fronts,” said Dr. Graham D. Jack, Xagenic’s senior director of Research and Development. “Under this joint program, we anticipate development of a new lower-cost substrate chip, which will significantly bring down the total cost of our in-cartridge AuRA™ detection technology.

Timothy I. Still appointed Xagenic’s president and CEO

On October 16, 2014, Xagenic also announced that Timothy I. Still has been appointed president and CEO, and will serve as a member of Xagenic Inc.’s board of directors.

This announcement was covered in PE Hub. (more…)

Whirlscape develops predictive keyboard for Will.i.am’s wearable Puls cuff

Whirlscape logoWhirlscape, makers of the Minuum keyboard, have developed a small, predictive keyboard for Will.i.am’s wearable Puls cuff. The company is a graduate of the UTEST program‘s first cohort.

The Puls, announced by the musician and entrepreneur on Wednesday, October 15, 2014 at the Salesforce.com’s Dreamforce conference in San Francisco, is expected to be released in time for the 2014 holiday season.

The Puls announcement and Whirlscape’s involvement were covered by Mashable.

Mashable’s Karissa Bell describes how Whirlscape’s keyboard integrates with the Puls:

Puls uses a small predictive keyboard that fits in the very bottom section of the screen. The keyboard was developed by Minuum, the Y Combinator-backed company that has also developed keyboards for Android Wear and Google Glass.

(more…)

Toronto Star features Minuum keyboard’s successful iPhone product launch

Whirlscape founders William Walmsley (left), Severin Smith and Xavier Snelgrove. The company is a graduate of the UTEST program's first cohort.

Whirlscape founders Will Walmsley (left), Severin Smith and Xavier Snelgrove. The company is a graduate of the UTEST program’s first cohort.

UTEST graduate Whirlscape was featured in Raju Mudhar’s Toronto Star article, “Toronto’s Whirlscape debuts tiny Minuum keyboard on iPhone,” which examines the company’s successful launch of their innovative, one-line keyboard for Apple’s iOS 8.

The UTEST program, co-directed by MaRS Innovation and the University of Toronto’s Innovations & Partnerships Office, gives nascent software companies start-up funding, office space, mentoring and business strategy support. Whirlscape was among the program’s first cohort.

The article was published October 6, 2014. Here’s an excerpt:

An Indiegogo success 18 months ago, the company created a tiny keyboard called Minuum for Android devices. Now, iOS and the vast Apple market beckoned. It required new hires, a couple months of round-the-clock development, and a practical rebuilding of their product from scratch so it could be ready to launch with iOS 8. All the work paid off: in the first two weeks of availability, they have sold more than 30,000 apps to the new iPhone audience. (more…)

MaRS Innovation joins new financing round for AvidBiologics Inc.

AvidBiologics Inc.TORONTO, Sept. 29, 2014AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC).

Led by Lumira Capital, the financing round included MaRS Innovation (MI), MaRS Investment Accelerator Fund (IAF), Rosseau Asset Management, and the company’s founding investors.

This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity.

Today’s financing builds on prior support from the Ontario Centres of Excellence (OCE), the National Research Council of Canada’s Industrial Research Assistance Program (NRC-IRAP), Ontario Ministry of Research and Innovation’s Business Accelerator Program (MRI-BAP) and other Canadian life science development organizations.

“This financing round enables us to rapidly advance our lead ADC into clinical trials,” said Ilia Tikhomirov, President and CEO. “We would like to thank the NRC and all of our partners for their support as AvidBiologics transitions from a discovery-stage to a development-stage company.”

Dr. Raphael Hofstein

Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

“The high quality pre-clinical package and exceptional leadership team, including pioneers in the development of ADCs, position the company for a successful transition towards clinical development,” said Dr. Raphael Hofstein, president and CEO of MI. “The cooperation among funding organizations, such as those involved in this financing, represents the strengthening foundation on which commercialization within Toronto’s start-up community can be successfully realized. We are glad to be part of this financing syndicate that supports one of Canada’s leading life sciences companies.” (more…)

Welcome to MaRS Innovation

MaRS Innovation commercializes the most promising research breakthroughs from 15 of Toronto’s top universities, institutions and research institutes. Our portfolio, built through over 1,000 intellectual property disclosures from our member institutions, turns discoveries into businesses through industry partnerships, licensing arrangements and start-up companies.

Subscribe for Portfolio News and Updates.

* required

*







Email & Social Media Marketing by VerticalResponse

Categories


Tags

Canada cancer commercialization in Canada commercialization in Ontario commercialization in Toronto early-stage investing early-stage seed funding early-stage technology entrepreneurship healthcare healthcare technologies Indiegogo licenseable technologies MaRS Discovery District media coverage MI Member Institutions minuum mobile technology Networks of Centres of Excellence Ontario Centres of Excellence (OCE) partnerships with industry Raphael (Rafi) Hofstein Ryerson University start-up companies Sunnybrook Health Sciences Centre Toronto University of Toronto University of Toronto Early Stage Technology (UTEST) UTEST Whirlscape


Archives